21172-28-1

Usage

Uses

Used in Pharmaceutical Research and Development:
2-Amino-1-[3-(trifluoromethyl)phenyl]ethanol is utilized as a building block in the synthesis of various pharmaceuticals due to its unique structural features. Its presence in the molecular structure can enhance the pharmacological properties of the resulting compounds, making it a valuable intermediate in drug discovery and development.
Used in Organic Synthesis:
In the realm of organic synthesis, 2-Amino-1-[3-(trifluoromethyl)phenyl]ethanol serves as a versatile intermediate. Its ability to participate in a range of chemical reactions allows for the creation of diverse organic substances, contributing to the advancement of organic chemistry.
Used in Organometallic Chemistry:
2-Amino-1-[3-(trifluoromethyl)phenyl]ethanol is employed as a ligand in organometallic chemistry. Its interaction with metal centers can lead to the formation of novel organometallic complexes with potential applications in catalysis and other areas of chemical research.
Used in Asymmetric Synthesis:
As a chiral auxiliary, 2-Amino-1-[3-(trifluoromethyl)phenyl]ethanol plays a crucial role in asymmetric synthesis. Its stereochemistry can be harnessed to control the enantioselectivity of chemical reactions, leading to the production of enantiomerically pure compounds, which are essential in the pharmaceutical industry to ensure the desired biological activity and safety of drugs.

InChI:InChI=1/C9H10F3NO/c10-9(11,12)7-3-1-2-6(4-7)8(14)5-13/h1-4,8,14H,5,13H2

Upstream product

• 7677-24-9 trimethylsilyl cyanide 
• 454-89-7 3-Trifluoromethylbenzaldehyde 
• 401-78-5 3-bromo-1-trifluoromethylbenzene 
• 82129-08-6 2-(3-Trifluoromethylphenyl)-2-trimethylsiloxyethanenitrile 
• 151-50-8 potassium cyanide 

Downstream Products

• 1184848-98-3 2-({6-[3-chloro-4-(trifluoromethyl)phenyl]pyrimidin-4-yl}amino)-1-[3-(trifluoromethyl)phenyl]ethanol 
• 1187984-03-7 tert-butyl {2-hydroxy-2-[3-(trifluoromethyl)phenyl]ethyl}carbamate 
• 83195-54-4 N-[2-(4-carbomethoxymethoxyphenyl)-1-methylethyl]-2-hydroxy-2-(3-trifluoromethylphenyl)-ethanamine 

Relevant academic research and scientific papers

1-Aryl-2-((6-aryl)pyrimidin-4-yl)amino)ethanols as competitive inhibitors of fatty acid amide hydrolase

A series of 1-aryl-2-(((6-aryl)pyrimidin-4-yl)amino)ethanols have been found to be competitive inhibitors of fatty acid amide hydrolase (FAAH). One member of this class, JNJ-40413269, was found to have excellent pharmacokinetic properties, demonstrated robust central target engagement, and was efficacious in a rat model of neuropathic pain.

Novel 1H-(benzimidazol-2-yl)-1H-pyridin-2-one inhibitors of insulin-like growth factor I (IGF-1R) kinase

A novel class of 1H-(benzimidazol-2-yl)-1H-pyridin-2-one inhibitors of insulin-like growth factor I (IGF-1R) kinase is described. This report discusses the SAR of 4-(2-hydroxy-2-phenylethylamino)-substituted pyridones with improved IGF-1R potency.

Discovery and optimisation of potent, selective, ethanolamine inhibitors of bacterial phenylalanyl tRNA synthetase

High throughput screening of Staphylococcus aureus phenylalanyl tRNA synthetase (FRS) identified ethanolamine 1 as a sub-micromolar hit. Optimisation studies led to the enantiospecific lead 64, a single-figure nanomolar inhibitor. The inhibitor series shows selectivity with respect to the mammalian enzyme and the potential for broad spectrum bacterial FRS inhibition.

1,4-benzodioxin derivatives

PCT No. PCT/JP96/01252 Sec. 371 Date Nov. 12, 1997 Sec. 102(e) Date Nov. 12, 1997 PCT Filed May 13, 1996 PCT Pub. No. WO96/35685 PCT Pub. Date Nov. 14, 1996A 1,4-benzodioxin derivative represented by formula (I) wherein A is an aryl group or a (C3-C8)cycloalkyl group, R1 and R2 individually are a hydrogen atom, a halogen atom, an alkyl group, a trifluoromethyl group, an alkoxy group, an aryl group, an aryloxy group, or R1 and R2 together form a methylenedioxy group, R3 is a hydrogen atom or an alkyl group, R4 is a hydrogen atom or CO2R5, R5 is a hydrogen atom or an alkyl group, X is a radical of formula (II) or (III) wherein n is 1 or 2. The compounds are useful for a prophylactic or therapeutic agent for diabetes, hyperglycemia and obesity.

Aromatic amino-alcohol derivatives having anti-diabetic and anti-obesity properties, their preparation and their therapeutic uses

Compounds of formula (I): STR1 (wherein: R0 is hydrogen, methyl or hydroxymethyl; R1 is substituted alkyl; R2 and R3 are each hydrogen, halogen, hydroxy, alkoxy, carboxy, alkoxycarbonyl, alkyl, nitro, haloalkyl, or substituted alkyl; X is oxygen or sulfur; and Ar optionally substituted phenyl or naphthyl); and pharmaceutically acceptable salts thereof have a variety of valuable pharmaceutical activities, including anti-diabetic and anti-obesity activities; in addition, they are capable of treating or preventing hyperlipemia and hyperglycemia and, by inhibiting the action of aldose reductase, they can also be effective in the treatment and prevention of complications of diabetes.

Oxazolidine derivatives having anti-diabetic and anti-obesity properties, their preparation and their therapeutic uses

Compounds of formula (I): STR1 wherein: R is an alkyl group; X is oxygen or sulfur; Y is hydrogen atom or --A--COOH, in which A is an alkylene group; Ar is aryl or substituted aryl group; and pharmaceutically acceptable salts and esters thereof, have use in the treatment or prophylaxis of diabetes, obesity, hyperlipemia, hyperglycemia, complications of diabetes, obesity-related hypertension and osteoporosis.

Secondary amines, their preparation and use in pharmaceutical compositions

Compounds having the formula: STR1 where R1, R2, R3, R4, R5, Y and X are as defined hereinbelow, are useful for the reduction of abnormally high blood glucose and lipid levels in the treatment of obesity or hyperglycaemia.